@article{af6b56dddb7645c2b28f7d633576a998,
title = "Palliative care in Duchenne muscular dystrophy: Goals of care discussions and beyond",
author = "Aravindhan Veerapandiyan and Rao, {Vamshi K.}",
note = "Funding Information: A.V. has worked in an advisory or consulting capacity with PTC Therapeutics, Novartis, Sarepta, Biogen, ScholarRock, Fibrogen, and NS Pharma, and has received grant or research support from Sarepta, Fibrogen, Novartis, Genentech, Amgen, Impax Labs, Teva, Ely Lilly, AMO Pharma, Pfizer, and Octapharma. V.R. has worked in advisory or consulting capacity for AveXis, Biogen, Genentech, Scholar Rock, NSPharma, Regenxbio, Sarepta, and PTC Therapeutics. V.R. has received grant or research support from NSPharma, Sarepta, Alexion, and Solid Biosciences. ",
year = "2022",
month = jun,
doi = "10.1002/mus.27544",
language = "English (US)",
volume = "65",
pages = "627--629",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "6",
}